A new combination of two different approaches – virotherapy
and immunotherapy - is showing “great promise” as a treatment for pancreatic
cancer, according to new research from QMUL.
The study, funded by the UK charity Pancreatic Cancer
Research Fund, investigated whether the effectiveness of the Vaccinia oncolytic
virus – a virus modified to selectively infect and kill cancer cells - as a
treatment for pancreatic cancer, would be improved by arming it with a gene
which modulates the body’s immune system.